Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.95 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.95 |
| ▸ | S1PR2 | O95136 | 11/20 | 0.65 |
| ▸ | S1PR1 | P21453 | 11/20 | 0.65 |
| ▸ | S1PR3 | Q99500 | 11/20 | 0.65 |
| ▸ | S1PR4 | O95977 | 9/20 | 0.65 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.65 |
| ▸ | TYMS | P04818 | 1/20 | 0.55 |
| ▸ | FDPS | P14324 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28012045 | 1.00 | LPAR3 (0.95) | LPAR3LPAR2S1PR2S1PR1S1PR3 | |
| SCHEMBL5701187 | 1.00 | LPAR3 (0.95) | LPAR3LPAR2S1PR2S1PR1S1PR3 | |
| SCHEMBL27374362 | 1.00 | LPAR3 (0.95) | LPAR3LPAR2S1PR2S1PR1S1PR3 | |
| SCHEMBL28941732 | 1.00 | LPAR3 (0.95) | LPAR3LPAR2S1PR2S1PR1S1PR3 | |
| SCHEMBL2521931 | 1.00 | LPAR3 (0.95) | LPAR3LPAR2S1PR2S1PR1S1PR3 | |
| SCHEMBL5701189 | 1.00 | LPAR3 (0.95) | LPAR3LPAR2S1PR2S1PR1S1PR3 | |
| SCHEMBL23037448 | 1.00 | LPAR3 (0.95) | LPAR3LPAR2S1PR2S1PR1S1PR3 | |
| SCHEMBL11472541 | 1.00 | LPAR3 (0.95) | LPAR3LPAR2S1PR2S1PR1S1PR3 | |
| SCHEMBL11474035 | 1.00 | LPAR3 (0.95) | LPAR3LPAR2S1PR2S1PR1S1PR3 | |
| SCHEMBL3823296 | 1.00 | LPAR3 (0.95) | LPAR3LPAR2S1PR2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102171225-B | The method of alkyl phosphonic acid, phosphonate ester and alkyl phosphonate is prepared in oxidation by means of phostonic acid, and their purposes | CLARIANT FINANCE (BVI) LTD. (VG) | 2015-09-09 | — | — | CN | disclosed |
| US-9018413-B2 | Method for the production of alkylphosphonic acids, esters, and salts by oxidizing alkylphosphonous acids, and use thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2015-04-28 | — | — | US | disclosed |
| US-20110251314-A1 | Method for the Production of Alkylphosphonic Acids, Esters, and Salts by Oxidizing Alkylphosphonous Acids, and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251314-A1 | Method for the Production of Alkylphosphonic Acids, Esters, and Salts by Oxidizing Alkylphosphonous Acids, and Use Thereof | ACSL3, SCO2, HAO2 | LPAR3 128/4885LPAR2 139/4885S1PR2 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.